Artículo de revista
Circulating miRNA-23b and miRNA-143 are potential biomarkers for In-Stent Restenosis
Fecha
2020Registro en:
BioMed Research International Volume 2020, Article ID 2509039, 6 pages
10.1155/2020/2509039
Autor
Saavedra, Nicolás
Rojas, Gabriel
Herrera, Jesús
Rebolledo, Camilo
Ruedlinger, Jenny
Bustos, Luis
Bobadilla, Braulio
Pérez, Luis
Saavedra, Kathleen
Zambrano Coloma, Tomás
Lanas, Fernando
Salazar, Luis A.
Institución
Resumen
In-stent restenosis (ISR) is one of the main complications in patients undergoing percutaneous coronary angioplasty, and microRNAs participate in the contractile-to-synthetic phenotypic switch of vascular smooth muscle cells, a hallmark of restenosis development. MicroRNAs (miRNAs) can be released into circulation from injured tissues, enticing a potential role as noninvasive biomarkers. We aimed to evaluate circulating levels of miRNA-23b, miRNA-143, and miRNA-145 as diagnostic markers of ISR. 142 patients with coronary artery disease undergoing successful angioplasty and a follow-up angiography were included. Subjects were classified according to the degree of obstruction at the angioplasty site into cases (>= 50%) or controls (<50%). Total RNA was isolated from plasma to quantify circulating miRNAs levels, and the ROC curves were constructed. Among circulating miRNAs assessed, miRNA-23b and miRNA-143 were significantly lower in cases (miRNA-23b:18.4x10-5and miRNA-143:13.7x10-5) than controls (miRNA-23b:5.2x10-5,p<0.0001; miRNA-143:4.0x10-5,p<0.0001). Plasma levels of miRNA-145 showed no significant differences. The analysis of the ROC curves showed an area under the curve for miRNA-23b of 0.71 (95% CI: 0.62-0.80,p<0.0001) and 0.69 for miRNA-143 (95% CI: 0.60-0.78;p<0.0001). Our data suggest that plasma levels of miRNA-23b and miRNA-143 could be useful as noninvasive biomarkers of ISR.